Molecular modeling and synthesis of certain substituted aryl compounds which have a potential anticancer activity

Aim: The enzyme methionine synthase (MetS) is linked to the cancer pathogenesis disorders such as myeloid leukemia, prostate and breast tumors. Inhibition of the biosynthesis of methionine amino acid which provides the tumor nucleic acid with one carbon atom building units occurred through the block...

Full description

Bibliographic Details
Main Author: Hosam A. Ahmed
Format: Article
Language:English
Published: Faculty of Pharmacy, Cairo University 2011-06-01
Series:Bulletin of Faculty of Pharmacy Cairo University
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S111009311100007X
_version_ 1797967108400742400
author Hosam A. Ahmed
author_facet Hosam A. Ahmed
author_sort Hosam A. Ahmed
collection DOAJ
description Aim: The enzyme methionine synthase (MetS) is linked to the cancer pathogenesis disorders such as myeloid leukemia, prostate and breast tumors. Inhibition of the biosynthesis of methionine amino acid which provides the tumor nucleic acid with one carbon atom building units occurred through the blocking of the natural substrate 5-methyltetrahydrofolate (MTHF) to bind to its binding domain in MetS with the synthesized compounds in this article. Design and methods: The target compounds were designed to interact with the binding site of MTHF in much the same way as the substrate. The crystal structure of MTHF binding region from human source has been deduced. A series of aromatic compounds was synthesized and docked separately into the MTHF binding site of the enzyme. Thermodynamic algorithms were done and compared to the results obtained from the biological cell line assay. Results: The cytotoxicity assay (in vitro) of the most potent compounds 2-hydroxymethyl-5-nitro-1H-benzimidazole and 1,3,5-trinitrobenzene showed IC50 of 50 ± 5 and 49 ± 5 μM, respectively, with score of the lowest free energy of binding −1610.42 and −1737.10 kJ/mol, respectively. Conclusion: The results of this study had led to the identification of two lead compounds with good inhibitory activities that could overlay for the next generation of the inhibitors for methionine synthase. Preparation of novel potential inhibitors for the methionine synthase that have the ability to avoid the side effects of the other marketed anticancer drugs could be a good step forward towards cancer treatment.
first_indexed 2024-04-11T02:26:00Z
format Article
id doaj.art-8131e571e2b2439b9a7a468a54a84033
institution Directory Open Access Journal
issn 1110-0931
language English
last_indexed 2024-04-11T02:26:00Z
publishDate 2011-06-01
publisher Faculty of Pharmacy, Cairo University
record_format Article
series Bulletin of Faculty of Pharmacy Cairo University
spelling doaj.art-8131e571e2b2439b9a7a468a54a840332023-01-02T22:47:03ZengFaculty of Pharmacy, Cairo UniversityBulletin of Faculty of Pharmacy Cairo University1110-09312011-06-01491253610.1016/j.bfopcu.2011.07.006Molecular modeling and synthesis of certain substituted aryl compounds which have a potential anticancer activityHosam A. AhmedAim: The enzyme methionine synthase (MetS) is linked to the cancer pathogenesis disorders such as myeloid leukemia, prostate and breast tumors. Inhibition of the biosynthesis of methionine amino acid which provides the tumor nucleic acid with one carbon atom building units occurred through the blocking of the natural substrate 5-methyltetrahydrofolate (MTHF) to bind to its binding domain in MetS with the synthesized compounds in this article. Design and methods: The target compounds were designed to interact with the binding site of MTHF in much the same way as the substrate. The crystal structure of MTHF binding region from human source has been deduced. A series of aromatic compounds was synthesized and docked separately into the MTHF binding site of the enzyme. Thermodynamic algorithms were done and compared to the results obtained from the biological cell line assay. Results: The cytotoxicity assay (in vitro) of the most potent compounds 2-hydroxymethyl-5-nitro-1H-benzimidazole and 1,3,5-trinitrobenzene showed IC50 of 50 ± 5 and 49 ± 5 μM, respectively, with score of the lowest free energy of binding −1610.42 and −1737.10 kJ/mol, respectively. Conclusion: The results of this study had led to the identification of two lead compounds with good inhibitory activities that could overlay for the next generation of the inhibitors for methionine synthase. Preparation of novel potential inhibitors for the methionine synthase that have the ability to avoid the side effects of the other marketed anticancer drugs could be a good step forward towards cancer treatment.http://www.sciencedirect.com/science/article/pii/S111009311100007XCrystal structureIC50InhibitionMethionine synthaseMethyltetrahydrofolate
spellingShingle Hosam A. Ahmed
Molecular modeling and synthesis of certain substituted aryl compounds which have a potential anticancer activity
Bulletin of Faculty of Pharmacy Cairo University
Crystal structure
IC50
Inhibition
Methionine synthase
Methyltetrahydrofolate
title Molecular modeling and synthesis of certain substituted aryl compounds which have a potential anticancer activity
title_full Molecular modeling and synthesis of certain substituted aryl compounds which have a potential anticancer activity
title_fullStr Molecular modeling and synthesis of certain substituted aryl compounds which have a potential anticancer activity
title_full_unstemmed Molecular modeling and synthesis of certain substituted aryl compounds which have a potential anticancer activity
title_short Molecular modeling and synthesis of certain substituted aryl compounds which have a potential anticancer activity
title_sort molecular modeling and synthesis of certain substituted aryl compounds which have a potential anticancer activity
topic Crystal structure
IC50
Inhibition
Methionine synthase
Methyltetrahydrofolate
url http://www.sciencedirect.com/science/article/pii/S111009311100007X
work_keys_str_mv AT hosamaahmed molecularmodelingandsynthesisofcertainsubstitutedarylcompoundswhichhaveapotentialanticanceractivity